NCT02013128 - Ublituximab + Ibrutinib in Select B-cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 6, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Chronic Lymphocytic LeukemiaMantle Cell Lymphoma

Interventions

DRUG

Ublituximab

Ublituximab (IV infusion)

DRUG

Ibrutinib

Ibrutinib oral daily dose

Trial Locations (18)

20817

TG Therapeutics Investigational Trial Site, Bethesda

22031

TG Therapeutics Investigational Trial Site, Fairfax

24060

TG Therapeutics Investigational Trial Site, Blacksburg

29615

TG Therapeutics Investigational Trial Site, Greenville

35805

TG Therapeutics Investigational Trial Site, Huntsville

38120

TG Therapeutics Investigational Trial Site, Memphis

60714

TG Therapeutics Investigational Trial Site, Niles

61801

TG Therapeutics Investigational Trial Site, Urbana

75230

TG Therapeutics Investigational Trial Site, Dallas

75702

TG Therapeutics Investigational Trial Site, Tyler

78705

TG Therapeutics Investigational Trial Site, Austin

80303

TG Therapeutics Investigational Trial Site, Boulder

85710

TG Therapeutics Investigational Trial Site, Tucson

93105

TG Therapeutics Investigational Trial Site, Santa Barbara

97213

TG Therapeutics Investigational Trial Site, Portland

97477

TG Therapeutics Investigational Trial Site, Springfield

98684

TG Therapeutics Investigational Trial Site, Vancouver

07962

TG Therapeutics Investigational Trial Site, Morristown

All Listed Sponsors

lead

TG Therapeutics, Inc.

INDUSTRY